Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 19

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
 $718,119  
    $2,292,576  
    $1,250,546 
  
    Denominator: 

    Weighted-average shares outstanding 
     23,000,000  
     10,517,143  
     19,110,497  
     10,424,325 
  
    Diluted net income per ordinary share 
    $0.07  
    $0.07  
    $0.12  
    $0.12 

    For The Period from May 23, 2024 (Inception) through June 30, 2024 

    Redeemable  
    Non-Redeemable 
  
    Basic and diluted net loss per share: 

    Numerator: 

    Allocation of net loss 
    $—  
    $(54,931)
  
    Denominator: 

    Weighted-average shares outstanding 
     —  
     8,571,429 
  
    Basic and diluted net loss per ordinary share 
    $—  
    $(0.01)

Recent Accounting Standards  

In November 2024, the FASB issued Accounting Standards
Update (“ASU”) 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses”, requiring public entities to disclose additional information about specific
expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years
beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company
is currently evaluating the impact of adopting ASU 2024-03. 

Management does not believe that any other recently
issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial
statement.

11

DRUGS MADE IN AMERICA ACQUISITION CORP.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2025

(Unaudited)

NOTE 3 — INITIAL PUBLIC OFFERING

Pursuant to the Initial Public Offering consummated
on January 29, 2025, the Company sold 20,000,000 Units at a price of $10.00 per Unit. Each